04 Jan '24
Prioritize the adenosine clinical candidates iNKT clinical development paused to focus resources Company will evaluate range of strategic options WESTPORT, Conn. , Jan. 04, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel